BrainStorm Cell Therapeutics Inc. Enters Into Agreement with FDA Specialist, PharmaNet, Inc., for the Development of ALS Human Clinical Trial Protocol in the USA  
7/22/2011 7:13:51 AM

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (BCLI.OB), an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm’s ALS human clinical trials in the United States.